In toxicological risk assessment the benchmark dose (BMD) is recommended instead of the no-observed-adverse effect-level (NOAEL). Still a simple test procedure to estimate NOAEL is proposed here, explaining its advantages and disadvantages. Versatile applicability is illustrated using four different data examples of selected in vivo toxicity bioassays.
翻译:在毒理学风险评估中,建议采用基准剂量,而不是无观测不良效应水平(NOAEL),但还是建议采用简单的测试程序来估计无观测不良效应水平,解释其利弊。